Literature DB >> 11499824

Medical advice for international travelers.

A Virk1.   

Abstract

Each year, approximately 30 to 40 million Americans travel outside the United States. Although the most popular destinations are Europe, Central America, and the Caribbean, travel to Africa and Asia is increasing substantially. International travel, particularly to developing countries, can be associated with the risk of infectious and noninfectious diseases. These risks can be decreased, eliminated, or modified with vaccinations, prophylactic medications, and education. Optimally, pretravel advice must be individualized to a person's medical history, itinerary, and risk behavior. In addition to risk assessment-based immunizations, issues such as traveler's diarrhea, malaria prophylaxis, sexually transmitted diseases, and management of underlying medical problems must form a part of pretravel management. Adventure or prolonged travel or persons with underlying medical diseases such as insulin-dependent diabetes mellitus, transplantation, immunodeficiencies, and dialysis warrant additional preventive measures. This review primarily updates pretravel management of adults.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499824     DOI: 10.1016/S0025-6196(11)63229-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Prevalence of the Sat gene among clinical isolates of Shigella spp. causing travelers' diarrhea: geographical and specific differences.

Authors:  Joaquim Ruiz; Margarita M Navia; Jordi Vila; Joaquim Gascón
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  A report on vaccine availability and administration protocols as of august 2002.

Authors:  Hugh Durham; George A Pankey
Journal:  Ochsner J       Date:  2002

Review 3.  Health risk of travel for chronic kidney disease patients.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Akio Namikawa; Hiroko Takahashi; Yuko Shibuya
Journal:  J Res Med Sci       Date:  2020-03-18       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.